Sushanta Mallick
No más puestos en curso
Perfil
Sushanta Mallick worked as Vice President-Research & Development at QLT, Inc. and as Head-Clinical Trial Management at ESBATech AG.
Mallick holds an MBA degree from The University of Texas at Austin and a doctorate degree from the University of North Texas.
Antiguos cargos conocidos de Sushanta Mallick.
Empresas | Cargo | Fin |
---|---|---|
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Director Técnico/Científico/I+D | - |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Corporate Officer/Principal | - |
Formación de Sushanta Mallick.
University of North Texas | Doctorate Degree |
The University of Texas at Austin | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
- Bolsa de valores
- Insiders
- Sushanta Mallick